TY - JOUR N2 - Neonatal sepsis, defi ned as sepsis occurring within the fi rst 28 days of life, is associated with signifi cant morbidity and mortality. It is undeniable that fi nding and appliance of biomarkers in clinical practice is of great importance, aiming at the early recognition of the impending clinical deterioration and the prompt and targeted therapeutic intervention. Aft er systematic and thorough research of the limited relevant literature, we attempt to present a documented point-of-view on the diagnostic value of TREM-1 and its soluble form both in early and late onset neonatal sepsis. L1 - http://www.czasopisma.pan.pl/Content/108790/PDF/FMC%202-18%202-Patoulias.pdf L2 - http://www.czasopisma.pan.pl/Content/108790 PY - 2018 IS - No 2 EP - 19 DO - 10.24425/fmc.2018.124655 KW - sepsis KW - neonate KW - TREM-1 KW - biomarker KW - specificity KW - sensitivity A1 - Patoulias, Dimitrios A1 - Kalogirou, Maria-Styliani A1 - Patoulias, Ioannis PB - Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum VL - vol. 58 DA - 2018.06.30 T1 - Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) and its soluble in the plasma form (sTREM-1) as a diagnostic biomarker in neonatal sepsis SP - 15 UR - http://www.czasopisma.pan.pl/dlibra/publication/edition/108790 T2 - Folia Medica Cracoviensia ER -